<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485858</url>
  </required_header>
  <id_info>
    <org_study_id>KPro-CIP-001</org_study_id>
    <nct_id>NCT04485858</nct_id>
  </id_info>
  <brief_title>First in Human (FIH) Study to Assess Safety and Efficacy of the CorNeat KPro for the Treatment of Corneal Blindness</brief_title>
  <official_title>Prospective, Open Label, Single Arm, First in Human (FIH) Clinical Study to Assess Safety and Efficacy of the CorNeat Keratoprosthesis for the Treatment of Corneal Blindness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CorNeat Vision Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CorNeat Vision Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open label, single arm, First in Human (FIH) clinical study to assess safety and&#xD;
      efficacy of the CorNeat Keratoprosthesis, a synthetic cornea, for the treatment of corneal&#xD;
      blindness&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this clinical study is to prove the safety and effectiveness of the CorNeat&#xD;
      Keratoprosthesis (KPro), a synthetic, artificial cornea for or the treatment of corneal&#xD;
      blindness in subjects who are not candidates for traditional corneal transplant.&#xD;
&#xD;
      Ten subjects who are willing to take part in the study will undergo screening examinations to&#xD;
      verify their eligibility.&#xD;
&#xD;
      The CorNeat KPro will be implanted unilaterally in eligible subjects. Follow up procedures&#xD;
      will be performed at 1 day, 1 week, 1, 2, 3, 6, 9 &amp; 12 months post implantation and will&#xD;
      include clinical assessment of the implanted eye using slit-lamp biomicroscopy, intra ocular&#xD;
      pressure measurement and ocular imaging. Additionally, subjects' visual acuity will be&#xD;
      assessed and recorded throughout the 12 months follow up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Endpoint as determined by the frequency and severity of all unanticipated adverse device-related events (UADE)</measure>
    <time_frame>Throughout the 12 months follow up period</time_frame>
    <description>The frequency and severity of all unanticipated adverse device-related events (UADE) or treatment-related adverse events, during and after implantation of the CorNeat KPro and up to 12 months should be less than SOC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary effectiveness Endpoint - Device retention rate</measure>
    <time_frame>12-months</time_frame>
    <description>Incidence of device retention as determined by slit-lamp biomicroscopy at last follow up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary effectiveness Endpoint - Improvement in BCDVA</measure>
    <time_frame>12-months</time_frame>
    <description>Improvement in BCDVA (using ETDRS visual acuity chart, where applicable) compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Corneal Disease</condition>
  <condition>Corneal Opacity</condition>
  <condition>Corneal Injuries</condition>
  <arm_group>
    <arm_group_label>CorNeat KPro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraocular implantation of the CorNeat KPro</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CorNeat KPro</intervention_name>
    <description>CorNeat KPro will be implanted into the subject's eye where the optic component snaps into the patient's trephined cornea and is sutured to the eye wall using 3 non-degradable sutures and the skirt component is placed under the conjunctiva</description>
    <arm_group_label>CorNeat KPro</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged ≥ 18 and ≤ 80 years on the day of screening&#xD;
&#xD;
          -  Candidates must have the ability and willingness to attend all scheduled visits and&#xD;
             comply with all study procedures&#xD;
&#xD;
          -  Keratoprosthesis surgery is indicated in cases when keratoplasty is not a reasonable&#xD;
             option or following a verifiable history of prior failed corneal transplantation&#xD;
&#xD;
          -  Indications that fall under poor candidate for keratoplasty include but are not&#xD;
             limited to: herpetic keratitis, vascularized corneal scar, Ocular Cicatricial&#xD;
             Pemphigoid, alkali burn, Steven Johnson Syndrome, and limbal stem cell deficiency&#xD;
&#xD;
          -  Pseudophakia&#xD;
&#xD;
          -  Adequate tear film and lid function&#xD;
&#xD;
          -  Perception of light in all quadrants&#xD;
&#xD;
          -  Female patients of childbearing age must have negative pregnancy test at screening and&#xD;
             agree to use an effective method of contraception throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reasonable chance of success with traditional keratoplasty&#xD;
&#xD;
          -  Current retinal detachment&#xD;
&#xD;
          -  Connective tissue diseases&#xD;
&#xD;
          -  End-stage glaucoma&#xD;
&#xD;
          -  History or evidence of severe inflammatory eye diseases (i.e. uveitis, retinitis,&#xD;
             scleritis) in one or both eyes within 6 months prior to planned implantation&#xD;
&#xD;
          -  History of ocular or periocular malignancy&#xD;
&#xD;
          -  History of extensive keloid formation&#xD;
&#xD;
          -  Any known intolerance or hypersensitivity to topical anaesthetics, mydriatics, or&#xD;
             component of the device&#xD;
&#xD;
          -  Signs of current infection, including fever and current treatment with antibiotics&#xD;
&#xD;
          -  Severe generalized disease that results in a life expectancy shorter than a year&#xD;
&#xD;
          -  Any clinical evidence that the investigator feels would place the subject at increased&#xD;
             risk with the placement of the device&#xD;
&#xD;
          -  Corneal thickness less than 400 or higher than 1,200 microns in any region of the&#xD;
             pachymetry map of the eye intended to be operated&#xD;
&#xD;
          -  Currently pregnant or breastfeeding&#xD;
&#xD;
          -  Participation in any study involving an investigational drug or device within the past&#xD;
             30 days or 5 half-lives of the drug (whichever longer) or ongoing participation in a&#xD;
             study with an investigational drug or device&#xD;
&#xD;
          -  Intraoperative complication that would preclude implantation of the study device&#xD;
&#xD;
          -  Vulnerable populations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerry Tal, B.Sc, MBA</last_name>
    <phone>+972 52-356-2826</phone>
    <email>gerry@corneat.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ido Klein, B.Sc, MBA</last_name>
    <phone>+972549350507</phone>
    <email>ido@corneat.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA - The Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ellen Pascual</last_name>
      <email>pascual@jsei.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony J Aldave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katie Hogeback</last_name>
      <phone>859-331-9000</phone>
      <phone_ext>4517</phone_ext>
      <email>khogeback@cvphealth.com</email>
    </contact>
    <investigator>
      <last_name>Edward Holland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3N9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandra Kuzmanovic</last_name>
      <phone>604 875 4555</phone>
      <email>akuzmanovic@shaw.ca</email>
    </contact>
    <investigator>
      <last_name>Alfonso Iovieno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Yeung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UHN - University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivera Sutakovic, MD</last_name>
      <phone>(416) 603-5800</phone>
      <phone_ext>5125</phone_ext>
      <email>olivera.sutakovic@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>David Rootman, MD, FRCS(C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clara Chan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie AUBERTIE</last_name>
      <phone>04.67.33.51.91</phone>
      <email>externe@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Daien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Vachey</last_name>
      <phone>0148036433</phone>
      <email>pvachey@for.paris</email>
    </contact>
    <investigator>
      <last_name>Eric Gabison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson</name>
      <address>
        <city>Petah tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilla German</last_name>
      <phone>9723-9376100</phone>
      <email>eyeclinic@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Irit Bahar, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eitan Livni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoav Nahum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC - Location AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Wezel</last_name>
      <phone>+31 20 5668618</phone>
      <email>m.wezel@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Ruth Lapid-Gortzak, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivanka van der Meulen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank van den Biggelaar, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Rudy Nuijts, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mor Dickman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Corneal Injuries</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
    <mesh_term>Corneal Opacity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

